JPMorgan Analysts Kasimov, Fye and Rama will host a conference call with CEO Clay Siegall on June 12 at 11 am.
It sounds great on the business sense to me that SGEN will now have access to the CAR-T/TCR/TIL technology to fight cancer. It may be a combination of ADC/CAR-T techology cancer therapy.
Please share with us your insight into this collaboration.
This is the D..est question of the year. Who is in his/her right mind to know SGEN to be bought out to answer your question? The only one who doesn't know anything will say..."I don't think so"..
VNDA will be on the block for sale as soon as it secures approval from EU.